RBC Bioscience

RBC Bioscience EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of RBC Bioscience (6848.TWO) as of Nov 6, 2026 is 17.52. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 43.76 — a change of -59.97% (lower).

EV/EBITDA

17.52

YoY

-59.97%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of RBC Bioscience is 2024 17.52 . EV/EBITDA (Enterprise Value to EBITDA) of RBC Bioscience was 2023 43.76 . It decreases by -59.97% lower compared to the previous year.

The RBC Bioscience EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
18.09 TWD
Jan 1, 2019
14.42 TWD
Jan 1, 2020
0.88 TWD
Jan 1, 2021
12.64 TWD
Jan 1, 2022
81.92 TWD
Jan 1, 2023
43.76 TWD
Jan 1, 2024
17.52 TWD
The RBC Bioscience EV/EBITDA history
YEAREV/EBITDAYoY
17.52-59.97%
43.76-46.58%
81.92+548.25%
12.64+1,331.43%
0.88-93.88%
14.42-20.30%
18.09—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RBC Bioscience Stock analysis

What does RBC Bioscience do? RBC Bioscience Corp manufactures reagents and devices for life science and molecular diagnosis. The company's products include instruments equipped with ultraviolet sterilization systems for nucleic acid purification and disposable reagent strips and tips that work with built-in control programs for different nucleic acid extraction types. The firm developed nucleic acid purification reagents with cellulose-embedded magnetic beads to improve DNA and RNA purity for blood, bacteria, viruses, and forensic examinations. These products are used for future diagnosis, prevention, tracking, and treatment of diseases. The company sells its instruments and reagents to customers in life science and molecular diagnosis sectors. The instruments feature ultraviolet sterilization systems, while the reagents include disposable strips and tips with varying control programs. The reagents with cellulose-embedded magnetic beads are designed for high-purity nucleic acid extraction from diverse samples including blood, bacteria, viruses, and forensic materials. RBC Bioscience Corp's revenue comes from the sale of instruments and reagents. The instruments are sold to laboratories and medical facilities requiring nucleic acid purification systems. The reagents, including the disposable strips and tips, are sold alongside the instruments or separately for ongoing use in molecular diagnosis processes. RBC Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RBC Bioscience stock

EV/EBITDA (Enterprise Value to EBITDA) of RBC Bioscience is 17.52 in 2024.

EV/EBITDA (Enterprise Value to EBITDA) of RBC Bioscience changed from 43.76 to 17.52, representing a -59.97% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) RBC Bioscience since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s RBC Bioscience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — RBC Bioscience

All Key Metrics — RBC Bioscience